Assessing the opportunities, considerations, and implications of decentralized trials—and why they're here to stay.
　　評(píng)估去中心化試驗(yàn)的機(jī)會(huì)、考慮因素和影響——以及為什么它們會(huì)存在保留.

For many pharmaceutical organizations, decentralized clinical trials （DCTs） have quickly become a strategic priority, one that is expected to endure long after the COVID-19 pandemic ends. Once viewed as nice-to-have pilot projects, DCTs—trials conducted remotely or through local healthcare providers to improve the patient experience—arrived when Pfizer launched a virtual trial1in 2011. While drug-based interventional DCTs only experienced a 7% CAGR between 2014 and 2019, they jumped to 77% between the second halves of 2019 and 2020 after the onset of COVID-19, according to ZS's DCT database, referencing data from more than 1,000 trials.
　　對(duì)于許多制藥企業(yè)而言，去中心化臨床試驗(yàn) （DCT） 已迅速成為其重點(diǎn)戰(zhàn)略，并預(yù)計(jì)在 COVID-19 大流行結(jié)束后仍將持續(xù)很長(zhǎng)時(shí)間。DCT（遠(yuǎn)程或通過(guò)當(dāng)?shù)蒯t(yī)療保健提供者進(jìn)行的試驗(yàn)以改善患者體驗(yàn)）在輝瑞于 2011 年啟動(dòng)虛擬試驗(yàn)1時(shí)出現(xiàn)時(shí)，曾經(jīng)被視為不錯(cuò)的試點(diǎn)項(xiàng)目。根據(jù) ZS 的 DCT 數(shù)據(jù)庫(kù)中參考1,000 多項(xiàng)試驗(yàn)的數(shù)據(jù)，在 2014 年和 2019 年，基于藥物的介入性 DCT 僅有7%CAGR，在 COVID-19 爆發(fā)后的 2019 年下半年和 2020 年之間，一躍攀升至 77%。

Decentralized trials offer a patient-centric approach, addressing various patient needs that often go unmet in traditional designs. DCTs benefit sponsors by accelerating clinical development, enabling more representative patient access and developing a stronger evidence package than traditional trials. Yet, DCT implementation doesn't have to be all or nothing； trial decentralization can be viewed as a spectrum, with most DCTs combining in-person and remote activities to make clinical trial participation easier for patients. But one thing is certain: COVID-19 has shifted the balance of tradeoffs for the pharma industry, and despite operational challenges that may arise during decentralization, the benefits outweigh the investment. In the era of disruption, now is the time to take the risk.
　　去中心化臨床試驗(yàn)提供了一種以患者為中心的方法，解決了傳統(tǒng)設(shè)計(jì)中經(jīng)常無(wú)法滿足的各種患者需求。DCT通過(guò)加速臨床研發(fā)、賦能典型患者接觸，并發(fā)展比傳統(tǒng)試驗(yàn)更有力的證據(jù)包，來(lái)使申辦方受益。然而，DCT的實(shí)施并不一定是1或0；試驗(yàn)去中心話可以被視為一個(gè)范圍，大多數(shù) DCT 結(jié)合了面對(duì)面和遠(yuǎn)程活動(dòng)，使患者更容易參與臨床試驗(yàn)。但有一件事是肯定的：COVID-19 改變了制藥行業(yè)的平衡，盡管去中心化可能會(huì)出現(xiàn)運(yùn)營(yíng)挑戰(zhàn)，但其收益大于投資。在顛覆的時(shí)代，現(xiàn)在是承擔(dān)風(fēng)險(xiǎn)的時(shí)候了。

DCTs are here to stay
　　DCT 將繼續(xù)存在

Through our work with pharma clients, we have observed four primary drivers that suggest DCTs are here to stay, even in a post-pandemic society:
　　通過(guò)我們與制藥客戶的合作，我們觀察到四個(gè)主要驅(qū)動(dòng)因素表明 DCT 將繼續(xù)存在，即使是在大流行之后的社會(huì)：

Regulatory direction:As a result of COVID-19, regulatory agencies including the FDA and European Medicines Agency have clarified their guidance on key decentralized modalities, such as telemedicine across state lines, direct-to-patient investigational product shipments, and more. The FDA's new Digital Health Center of Excellence2and legislative direction3to advance the use of DCTs indicate a smoother regulatory landscape through 2021 and beyond.
　　監(jiān)管方向：由于 COVID-19，包括 FDA 和歐洲藥品管理局在內(nèi)的監(jiān)管機(jī)構(gòu)已經(jīng)明確了他們對(duì)關(guān)鍵分散模式的指導(dǎo)，例如跨州遠(yuǎn)程醫(yī)療、直接面向患者的研究產(chǎn)品運(yùn)輸?shù)?。FDA 新的數(shù)字健康卓越中心和立法方向以推進(jìn) DCT 的使用，表明到 2021 年及以后監(jiān)管環(huán)境將更加順暢。

Technology maturity:Evolving technology—fueled by record-level venture capital investments4in digital health—is enabling trial decentralization. Furthermore, horizontal and vertical integration among technology solution providers is creating more end-to-end technology solutions to deliver DCTs.
　　技術(shù)成熟度：不斷發(fā)展的技術(shù)——在數(shù)字健康領(lǐng)域創(chuàng)紀(jì)錄的風(fēng)險(xiǎn)資本投資的推動(dòng)下——正在驅(qū)動(dòng)試驗(yàn)去中心化。此外，技術(shù)解決方案提供商之間的橫向和縱向整合正在創(chuàng)造更多的端到端技術(shù)解決方案來(lái)實(shí)現(xiàn)DCT。

Pharma investment and capability development:Pharma is creating focused DCT capability groups with dedicated leadership and investing in processes and technology to operate DCTs at scale.
　　制藥投資和能力開(kāi)發(fā)：制藥公司正在創(chuàng)建專注于DCT的小組，具有專門(mén)的領(lǐng)導(dǎo)人員，并投入流程和技術(shù)以大規(guī)模運(yùn)營(yíng)DCT。

Patient experience:Patients' increasing use of digital healthcare, such as telemedicine and digital pharmacies, have enhanced expectations of their clinical trial experience, which we don't expect to revert moving forward.
　　患者體驗(yàn)：患者越來(lái)越多地使用數(shù)字醫(yī)療保健，例如遠(yuǎn)程醫(yī)療和數(shù)字藥房，提高了對(duì)其臨床試驗(yàn)體驗(yàn)的期望，這種情況我們預(yù)計(jì)未來(lái)不會(huì)逆轉(zhuǎn)。

Pros and cons of DCTs
　　DCT的優(yōu)缺點(diǎn)

DCTs offer patients a more streamlined experience, reduce the burden of time-consuming in-person visits and enable wider patient access, especially in rural and underrepresented communities.
　　DCT 為患者提供了更簡(jiǎn)化的體驗(yàn)，減少了耗時(shí)就診的負(fù)擔(dān)，并能更廣泛地接觸患者，尤其是在農(nóng)村和社區(qū)。

Like patients, sponsors also benefit from DCTs. As of 2016, 85% of trials failed to finish on time, financially impacting sponsors by up to $8 million per day, according to Pharmafile.5Decentralization can reduce these hurdles for sponsors by speeding up recruitment, increasing compliance, and reducing drop-out rates. Additionally, collecting high-quality clinical and real-world data through DCTs can build stronger evidence packages and better reflect the value created for patients. Sponsors can use novel digital endpoints to generate differentiated label claims through DCTs as well.
　　與患者一樣，申辦方也受益于DCT。根據(jù) Pharmafile 的數(shù)據(jù)，截至 2016 年85% 的試驗(yàn)未能按時(shí)完成，對(duì)申辦方每天的財(cái)務(wù)影響高達(dá) 800 萬(wàn)美元。去中心臨床試驗(yàn)可以通過(guò)加快招募、提高合規(guī)性和降低退出率來(lái)減少申辦方面臨的這些障礙. 此外，通過(guò) DCT 收集高質(zhì)量的臨床和現(xiàn)實(shí)世界數(shù)據(jù)，可以構(gòu)建更強(qiáng)大的證據(jù)包，并更好地反映為患者創(chuàng)造的價(jià)值。通過(guò)DCT,申辦方也可以使用新穎的數(shù)字端點(diǎn)生成差異化的標(biāo)簽聲明。

Still, decentralization—like most new innovations—adds complexity to the clinical trial process. It requires stakeholders to devote time and resources before the benefits can be realized. Sponsors must learn how to effectively and flexibly implement DCTs, as well as support patients and sites on their respective learning journeys. From a regulatory perspective, DCTs are still nascent and without consistent standards, meaning sponsors may have to initially focus on select priority markets. Lastly, while initial proof points to DCTs providing value are emerging—especially for increasing recruitment speed6and enhancing patient retention7—more work is needed to understand their impact. Sponsors should consider ways to benchmark DCT performance versus traditional trials to understand and capture the value of DCT.
　　盡管如此，去中心化——與大多數(shù)新的創(chuàng)新一樣——增加了臨床試驗(yàn)過(guò)程的復(fù)雜性。它需要利益相關(guān)者投入時(shí)間和資源才能實(shí)現(xiàn)收益。申辦方必須學(xué)習(xí)如何有效和靈活地實(shí)施 DCT，并在各自的學(xué)習(xí)過(guò)程中支持患者和site。從監(jiān)管的角度來(lái)看，DCT仍處于起步階段沒(méi)有一致的標(biāo)準(zhǔn)，這意味著申辦方可能必須首先關(guān)注特定的優(yōu)先市場(chǎng)。最后，雖然 DCT提供價(jià)值的初步證據(jù)正在出現(xiàn)——尤其是在提高招募速度 6 和提高患者保留率方面——但還需要做更多的工作來(lái)了解它們的影響。申辦方應(yīng)考慮對(duì) DCT 性能與傳統(tǒng)試驗(yàn)進(jìn)行基準(zhǔn)測(cè)試的方法，以了解和獲取 DCT 的價(jià)值。

Key considerations and implications
　　主要考慮因素和影響

Sponsors considering DCTs must root their approach in a deep understanding of patient needs and experiences. Designing approaches and solutions that reduce the patient burden and provide the right behavioral incentives for patients will lead to better patient engagement and improved trial performance. It's also important to recognize that sites will remain key to patient experiences: As sponsors develop DCT solutions, providing options that are adaptive to site workflow and capability will be critical.
　　考慮 DCT 的申辦方,必須將他們的方法基于對(duì)患者需求和體驗(yàn)的深刻理解。設(shè)計(jì)減輕患者負(fù)擔(dān)并為患者提供正確行為激勵(lì)的方法和解決方案將引導(dǎo)更好的患者參與及改進(jìn)臨床試驗(yàn)績(jī)效。意識(shí)到site仍是患者體驗(yàn)的關(guān)鍵也很重要：隨著申辦方開(kāi)發(fā)DCT解決方案，提供適合site工作流程和能力的選擇將是至關(guān)重要的。

It's easy to assume solely decentralizing trials and introducing new technology will improve the patient experience, but this isn't necessarily true. In fact, a multitude of disjointed study apps may even increase the burden, while home nurse visits may be more stressful than visiting a community center. Sponsors must first listen to patients and understand their needs, and then create a more personalized trial experience that meets those needs. It's important for sponsors with diverse clinical development pipelines to tailor this exercise to specific trial patient populations, endpoints and intervention modalities. Furthermore, within each trial, sponsors should strive to enable optionality for individual patients based on their engagement preferences.
　　很容易假設(shè)僅去中心化臨床試驗(yàn)和引入新技術(shù)將改善患者體驗(yàn)，但這不一定是真的。事實(shí)上，大量雜亂無(wú)章的學(xué)習(xí)應(yīng)用程序甚至可能會(huì)增加負(fù)擔(dān)，而家庭護(hù)士訪問(wèn)可能比訪問(wèn)社區(qū)中心更具壓力。申辦方首先必須聽(tīng)取患者的意見(jiàn)并了解他們的需求，然后創(chuàng)建可以滿足這些需求的更加個(gè)性化的試驗(yàn)體驗(yàn)。對(duì)于擁有不同臨床開(kāi)發(fā)渠道的申辦方來(lái)說(shuō)，根據(jù)特定的試驗(yàn)患者群體、終點(diǎn)和干預(yù)方式定制這項(xiàng)練習(xí)非常重要。此外，在每項(xiàng)試驗(yàn)中，申辦方應(yīng)努力根據(jù)個(gè)別患者的參與偏好為他們提供選擇權(quán)。

Beyond the approach itself, sponsors also must ensure that decentralization options are considered early in clinical development planning, allowing sufficient time for patient research, endpoint validation and vendor selection activities. If decentralization is an operational afterthought, the process will be more difficult to incorporate and, moreover, the extent to which the trial can be decentralized will be constrained by traditional, site-centered protocols. Shifting this thinking upstream will enable study teams to assess how decentralization can improve the patient experience.
　　除了方法本身，申辦方還必須確保在臨床開(kāi)發(fā)計(jì)劃的早期考慮去中心化的選擇，為患者研究、終點(diǎn)驗(yàn)證和供應(yīng)商選擇活動(dòng)留出足夠的時(shí)間。如果去中心化是事后的想法，則該過(guò)程將更難以納入，而且，試驗(yàn)的去中心化程度將受到傳統(tǒng)的、以site為中心的協(xié)議的限制。將這種想法向上游轉(zhuǎn)移將使研究團(tuán)隊(duì)能夠評(píng)估去中心化如何改善患者體驗(yàn)。

Developing the digital capabilities needed for DCTs is also critical. There are new types of data collected in DCTs and oftentimes new insight generation opportunities from continuous data collection. Digital solutions must enable a unified user experience and one source of truth for data integration. Additionally, while the infrastructure can be gradually built—with numerous digital solutions and providers in the market—sponsors must have an enterprise architecture blueprint to guide the development to enable connectivity and optionality. Developing the DCT infrastructure without a plan would lead to future challenges with technological integration and agility.
　　發(fā)展DCT所需的數(shù)字能力也很關(guān)鍵。在 DCT 中收集了新類型的數(shù)據(jù)，并且經(jīng)常從連續(xù)數(shù)據(jù)收集中獲得新的視角及機(jī)會(huì)。數(shù)字解決方案必須支持統(tǒng)一的用戶體驗(yàn)和數(shù)據(jù)集成的一個(gè)真實(shí)來(lái)源。此外，雖然基礎(chǔ)設(shè)施可以逐步構(gòu)建——市場(chǎng)上有許多數(shù)字解決方案和供應(yīng)商——但申辦方必須有一個(gè)企業(yè)架構(gòu)藍(lán)圖來(lái)指導(dǎo)開(kāi)發(fā)以實(shí)現(xiàn)連接性和可選性。在沒(méi)有計(jì)劃的情況下開(kāi)發(fā) DCT 基礎(chǔ)設(shè)施將導(dǎo)致未來(lái)的技術(shù)集成和敏捷性挑戰(zhàn)。

Finally, since DCTs are cross-functional in nature, they require collaboration across sponsors' trial design, trial operations, regulatory, digital health and innovation functions. These teams must overcome functional silos and establish new ways of working to successfully drive DCTs. Sponsors must also establish consistent processes to facilitate scaling DCTs from a proof-of-concept to an organizational capability. One key step here is organizational knowledge sharing: applying learnings rapidly and efficiently across study teams.
　　最后，由于 DCT 本質(zhì)上是跨職能的，因此它們需要在申辦方的試驗(yàn)設(shè)計(jì)、試驗(yàn)運(yùn)營(yíng)、監(jiān)管、數(shù)字健康和創(chuàng)新職能之間進(jìn)行協(xié)作。這些團(tuán)隊(duì)必須克服功能孤島并建立新的工作方式以成功推動(dòng) DCT。申辦方還必須建立統(tǒng)一的流程，以促進(jìn) DCT 從概念驗(yàn)證到組織能力的擴(kuò)展。這里的一個(gè)關(guān)鍵步驟是組織知識(shí)共享：跨研究團(tuán)隊(duì)快速有效地應(yīng)用學(xué)習(xí)。

Where to start?
　　從哪里開(kāi)始？

For sponsors wondering where to begin or focus DCT efforts across a portfolio, a combination of their business needs and the feasibility of decentralization between therapy areas can act as a guide. Some therapy areas are a better fit for decentralized trials, based on factors such as the investigational medicinal product's administration route （e.g., oral vs. infusion）, type of assessment procedure （e.g., non-invasive vs. invasive biopsy）, and whether the condition being studied is chronic or acute. Although ZS's DCT database found cardiovascular, neurology, and diabetes as the most common therapy areas for DCTs, they can also be applied in other therapeutic areas. In fact, oncology and infectious diseases makeup 5% and 4%, respectively, of all DCTs historically. That said, for many therapy areas, full decentralization may not be feasible or right for patients； instead, identifying specific procedures that can be decentralized or combined into a single visit can drive valuable improvements to the patient experience.
　　對(duì)于想知道從哪里開(kāi)始或在整個(gè)投資組合中集中 DCT工作的發(fā)起人來(lái)說(shuō)，他們的業(yè)務(wù)需求和治療領(lǐng)域之間去中心化的可行性的組合可以作為指導(dǎo)。一些治療領(lǐng)域更適合分散試驗(yàn)，這取決于研究藥物的給藥途徑（例如，口服與輸注）、評(píng)估程序類型（例如，非侵入性與侵入性活檢）以及病情是否正在研究的是慢性的或急性的。盡管 ZS 的 DCT 數(shù)據(jù)庫(kù)發(fā)現(xiàn)心血管、神經(jīng)病學(xué)和糖尿病是 DCT 最常見(jiàn)的治療領(lǐng)域，但它們也可以應(yīng)用于其他治療領(lǐng)域。事實(shí)上，腫瘤學(xué)和傳染病歷來(lái)分別占所有 DCT 的 5% 和 4%。也就是說(shuō)，對(duì)于許多治療領(lǐng)域，完全分散對(duì)患者來(lái)說(shuō)可能不可行或不正確。相反，確定可以分散或合并到單次訪問(wèn)中的特定程序可以推動(dòng)對(duì)患者體驗(yàn)的寶貴改進(jìn)。

As DCTs become more common, they will raise the bar for patient experience and patient data collection. They offer an opportunity to fundamentally change how we perform clinical research. As pharma companies embark on this journey, they can't do it alone. The good news is that patients, investigators, sites and regulators are prepared to make the change and unlock the value of moving clinical trials closer to patients.
　　隨著 DCT變得越來(lái)越普遍，它們將提高患者體驗(yàn)和患者數(shù)據(jù)收集的標(biāo)準(zhǔn)。它們提供了從根本上改變我們進(jìn)行臨床研究的方式的機(jī)會(huì)。隨著制藥公司踏上這一旅程，他們無(wú)法獨(dú)自完成。好消息是，患者、研究人員、研究中心和監(jiān)管機(jī)構(gòu)已準(zhǔn)備好做出改變并釋放讓臨床試驗(yàn)更貼近患者的價(jià)值。

Fan Gaois aPrincipal；Maurice Solomonis a Principal；Arnab Royis a Manager； andWilliam Chaplinis a Consultant, all withZS

以上文章手翻自外網(wǎng)，如有翻譯錯(cuò)誤，敬請(qǐng)諒解。
　　來(lái)源：煎茶員日記